Porównaj metody

	EORTC QLQ-C30	Dermatology Life Quality Index (DLQI)
Dziedzina	Wyniki zdrowotne	Wyniki zdrowotne
Rodzina	Process / pipeline	Process / pipeline
Rok powstania	1993	1994
Twórca	Nico Aaronson et al.	Andrew Y. Finlay and Gul K. Khan
Typ	Self-report quality of life questionnaire	Self-report quality of life questionnaire
Źródło pierwotne	Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.	Finlay, A. Y., & Khan, G. K. (1994). Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210-216.
Inne nazwy	QLQ-C30, EORTC QLQ-C30, Cancer Quality of Life Scale	DLQI, Finlay Index, Dermatology Quality of Life
Pokrewne	5	3
Podsumowanie	The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care.	The DLQI is the primary patient-centered outcome measure in dermatology research and clinical practice. Developed by Andrew Finlay and Gul Khan in 1994, this 10-item self-report questionnaire quantifies the impact of skin disease on patients' daily functioning, emotional well-being, social relationships, and work capacity. It is simple, rapid, and applicable to virtually all dermatological conditions, making it the gold standard for assessing quality of life in dermatology.